Strategic CEO Advisor, Coach
Jeffrey M. Arnold, Strategic CEO Advisor and Exectutive Coach

About Me


I work with talented CEO’s in life sciences to build the business, overcome challenges, and avoid mistakes. I can help refine the business plan, raise money, build the team, improve marketing and grow sales, develop strategic partnerships and achieve an exit. 

A CEO of multiple companies over 20 years and CEO advisor and investor since 2005, I have faced at one time or another most of the challenges faced by CEO's of early and growth companies -- likely multiple times. Before becoming a CEO, I worked in R&D, marketing and operations for Fortune 500 and smaller companies. This varied background allows me to look at problems from multiple perspectives.


See what other CEO's say about working with me.


Trusted Advisor / Investor


My door is always open on an informal basis to entrepreneurs and CEO's looking for advice and/or introductions. I look for nothing in return but an opportunity to help.  As a member of three local angel investment groups I am happy to help promising companies gain access to angel capital.


For one or two companies a year, I do more than that -- invest personally, become a formal strategic advisor / part time member of the team and advocate of the company to investors, potential partners and key customers. These relationships most often last from the first angel round to the ultimate exit.

Of the 15 companies where I invested and became a formal advisor, more than half (8) have already exited and five are doing well and likely on their way to exit.

Please contact me if you think I might be of help.




Company News

Glympse Bio, Inc. Raises $22m Series A Financing

CAMBRIDGE, Mass., October 9, 2018 -- (BUSINESS WIRE)--Glympse Bio, Inc. announced today that it has raised $22 million in Series A funding. The proceeds of this round will be devoted to conducting clinical trials for its novel platform which uses bioengineered activity sensors to noninvasively detect human diseases and to monitor drug response. Glympse Bio is a spin-out from the laboratory of Sangeeta Bhatia, M.D., Ph.D. at the Massachusetts Institute of Technology.

scPharmaceuticals Inc. Announces Closing of Initial Public Offering

BURLINGTON, Mass., Nov. 29, 2017 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (the “Company”) a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs, today announced the closing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $14.00 per share.  All of the shares sold in the offering were offered by scPharmaceuticals. scPharmaceuticals common shares began trading on The Nasdaq Global Select Market under the ticker symbol “SCPH” on November 17, 2017.

Aras Announces $40 Million Investment Led by Silver Lake

ANDOVER, Mass. and Tokyo, Japan – September 6, 2017 – Aras®, the next leader in enterprise Product Lifecycle Management (PLM) software, today announced a $40 million investment round led by Silver Lake Kraftwerk, a fund of Silver Lake, the global leader in technology investing, with participation from GE Ventures, the investment arm of General Electric. Aras will use this minority investment to drive growth, expand operations - including Aras’ world-class service and support - and further extend Aras’ technology leadership through development and acquisitions.

Corbus Pharmaceuticals Announces Inclusion in Russell 3000(R) Index

NORWOOD, MA -- (Marketwired) -- 06/26/17 -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it was added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution on June 23, 2017.

Myomo, Inc. Trades On The New York Stock Exchange MKT

Cambridge, MA., June 12, 2017 – Myomo, Inc. (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that following the close of its initial public offering, its common shares will begin trading on the New York Stock Exchange (NYSE) MKT sometime after 9:30 AM EDT, under the symbol "MYO.” Myomo is the first Regulation A+ issuer to list its securities on a national exchange.

Intrinsic Therapeutics Announces the Completion of a $49M Financing

Boston, MA- May 10, 2017 -8:00am EST – Intrinsic Therapeutics, Inc. a medical device company that has developed a product to improve outcomes in lumbar discectomy patients, announced today that it recently closed a $49 million round of financing.  

Astrocyte Pharmaceuticals Raises Over $1.3M in Seed Financing Round

Cambridge, MA, March 24, 2017 – Astrocyte Pharmaceuticals Inc., a CNS therapeutics startup, announced today that it has raised approximately $1.36M in a seed financing round.  The company is developing novel small molecule drugs that limit neuronal damage in patients that have suffered a stroke, traumatic brain injury (TBI) or concussion.


The seed financing round was led by Boston Harbor Angels, and joined by the University of Texas Horizon FundSideCar Angels and others.

Please reload

What CEO's Say

"He has been an invaluable contributor to our success."

Sangeeta Bhatia, founding CEO, Glympse Bio

“Jeff zeroed in on the essential issues like no one I ever met.”

Scot Jones, CEO and owner, Groov-Pin, Corp.

"He cares as much about your success as you do.  I always feel like he has my back."

Phil Johnson, CEO and owner, PJA Advertising

"He has had a material impact on the rapid growth and success of our business."

Rick Green, CEO and owner, 1A Auto

"I get incredible value out of every meeting."

Cary Hagan, CEO, Intrinsic Therapeutics

"He has a way of cutting through the noise to get to the substance quickly."

Murat Kalayoglu, former CEO, Health Honors

"Jeff has been an invaluable asset."

Steve Gordon, Intelligent BioSystems

"You rarely find someone with Jeff’s intellect, experience and willingness to be there for you."

Fred Kornahrens, former CEO, Kspine

Please reload

Featured Posts
Speaking Events

UMASS / M2D2 Baracuda Bowl

October 12, 2017 - Judge a shark tank like event for promising life science companies. Learn more. 

Boston Bar Association Life Science Conference

October 3, 2017 - Moderate a panel of distinguished venture investors on technology trends in life sciences and life science investing. Learn more.

Redesigning Life Science Investments (RESI) Conference, Panel on Angel Biotech Investments

September 27, 2107 - Moderate a panel of distinguished angel investors on the current state and practice of obtaining angel investment in biotech companies. Learn more. 

Please reload